Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Ramatroban
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II/ Phase III
Sponsor : BARDA
Deal Size : Undisclosed
Deal Type : Funding
Details : Ramatroban (KARE 101), a dual blocker of thromboxane and prostanoid receptors, has demonstrated efficacy in animal models of respiratory dysfunction, atherosclerosis, thrombosis, and sepsis, and evidence for rapid relief of dyspnea and hypoxemia in COVID...
Product Name : KARE 101
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
May 10, 2022
Lead Product(s) : Ramatroban
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II/ Phase III
Sponsor : BARDA
Deal Size : Undisclosed
Deal Type : Funding
Reset All
